Beihai Bio Secures Series A+ Financing Within a Year of Two Rounds to Accelerate Clinical Development of Innovative Oncology Drugs

Recently, Beihai Biotech, a clinical-stage biotechnology company focused on developing innovative oncology drugs, announced the completion of its Series A+ financing round.This financing round was jointly completed by Yikai Venture Capital and Guozhong Capital.Beihai Biotech completed two rounds of financing in 2021. The proceeds from this round will be primarily used to advance Phase I/II clinical studies of several core products, as well as to support ongoing preclinical research and clinical development targeting innovative therapeutic targets.

Beihai Biotech has always adhered to source innovation, possessing two proprietary original drug technology platforms. Its dual-engine strategy has enabled a series of product layouts in the field of innovative oncology drugs. The company boasts more than 10 R&D pipelines that are both differentiated and innovative. To date, it has obtained three clinical trial approvals in China and two in the United States. Among these, three new drug projects are currently in clinical stages:

1) BH009 is an innovative docetaxel product independently developed by Beihai Biotech using its globally pioneering solubilization and delivery technology platform for poorly soluble drugs. It possesses full independent intellectual property rights, and key clinical trials for BH009 have been conducted overseas.

2) BH002 has entered Phase I clinical trials for the treatment of advanced prostate cancer.

3) BH011 has entered Phase I/II clinical trials for the treatment of non-muscle-invasive bladder cancer.

Dr. Sun Qun, Founder and Chairman of Beihai BiotechStatement: “It is deeply gratifying to have once again gained the recognition of investment institutions within just a few months after completing our Series A financing. We extend our sincere gratitude to all shareholders for their unwavering support throughout Beihai Biotech’s development journey. I am confident that this round of financing will help accelerate the clinical trial progress of Beihai’s core products and provide strong support for building our team of high-end talent. We firmly believe that Beihai Biotech’s unique R&D technology platform, rich product pipeline, and clinical development strategy hold substantial market prospects and investment potential.”

Beihai Biotech is a clinical-stage biopharmaceutical company dedicated to developing innovative oncology drugs that address unmet clinical needs with a patient-centric approach. The company possesses a globally first-in-class new drug platform technology and sustained innovation capabilities. It has strategically established a pipeline of more than 10 differentiated innovative drug candidates. Through independent research and development, Beihai Biotech has filed over 70 invention patent applications and has been granted 15 invention patents in China, the United States, the European Union, and other jurisdictions.

Currently, Beihai Biotech has obtained five Investigational New Drug (IND) approvals in China and the United States, with multiple projects having entered the clinical research stage.

Beihai Biotech remains committed to source innovation as its core driving force, identifying and addressing unmet clinical needs. Adhering to a development strategy of “global vision, focus on clinical value,” the company continuously develops safe and effective oncology drugs urgently needed in clinical practice, providing better treatment options for cancer patients worldwide and striving to become a world-class biopharmaceutical enterprise in the field of oncology.